Evidence map›Paper›PMID 41369741›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Oral antibiotics: even in severe infections?]

Rika Draenert, Johannes Bogner, Alexandra Weber

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rika DraenertStabsstelle ABS, LMU Klinikum, Campus Großhadern, Marchioninistr. 15, 81377, München, Deutschland. rika.draenert@med.uni-muenchen.de.
Johannes BognerMedizinische Klinik und Poliklinik IV, LMU Klinikum, München, Deutschland.
Alexandra WeberStabsstelle ABS, Apotheke, LMU Klinikum, München, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous antibiotic therapy has traditionally been considered the standard treatment for severe infections. However, recent research shows that early switching to oral antibiotics is often equivalent or even superior. This is made possible by new substances with high oral bioavailability and numerous clinical studies demonstrating the safety and efficacy of oral sequential therapy. Sequential therapy has advantages for patients (fewer catheter complications, better mobility and quality of life) and is beneficial both economically (lower costs, shorter hospital stays, fewer nosocomial infections) and ecologically (less waste). For various serious infections such as bone and joint infections, complicated urinary tract infections and severe pneumonia-as well as for endocarditis and bloodstream infections when certain conditions are met-studies show that switching to oral antibiotics is safe as soon as the patient is clinically stable. The selection of the appropriate oral agent is crucial and depends on bioavailability, the causative pathogen and the severity of the infection. Possible interactions with food and other medications must be taken into account.

Indexed as

Anti-Bacterial AgentsBacterial InfectionsAdministration, OralBiological AvailabilityHumansAnti-Bacterial AgentsAdministration, oral/anti-bacterial agentsBiological availability/anti-bacterial agentsBloodstream infectionEndocarditisOsteomyelitisUrinary tract infections, complicated

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.